Literature DB >> 6959564

Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity.

S S Legha, Y M Wang, B Mackay, M Ewer, G N Hortobagyi, R S Benjamin, M K Ali.   

Abstract

Our data indicate that alpha-tocopherol used in an oral dose of 2 g/m2 daily results in a six- to eightfold increase of the vitamin E levels in serum. The occurrence of congestive heart failure in three patients and the observation of significant pathologic changes in endomyocardial biopsies in approximately half of the patients treated with a median cumulative adriamycin dose level of 550 mg/m2 indicate that alpha-tocopherol does not offer substantial protection against adriamycin-induced cardiac toxicity. The antitumor activity of the drug, however, is not compromised by the concomitant administration of the vitamin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6959564     DOI: 10.1111/j.1749-6632.1982.tb31279.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Advances in the use of tocols as drug delivery vehicles.

Authors:  Panayiotis P Constantinides; Jihong Han; Stanley S Davis
Journal:  Pharm Res       Date:  2006-01-25       Impact factor: 4.200

2.  Protective effects of the glutathione redox cycle and vitamin E on cultured fibroblasts infected by Mycoplasma pneumoniae.

Authors:  M Almagor; I Kahane; C Gilon; S Yatziv
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

5.  Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death.

Authors:  Satoru Kobayashi; Paul Volden; Derek Timm; Kai Mao; Xianmin Xu; Qiangrong Liang
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

6.  Beet root juice protects against doxorubicin toxicity in cardiomyocytes while enhancing apoptosis in breast cancer cells.

Authors:  Sayantanee Das; Scott M Filippone; Denise S Williams; Anindita Das; Rakesh C Kukreja
Journal:  Mol Cell Biochem       Date:  2016-08-26       Impact factor: 3.396

Review 7.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

8.  Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

10.  Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

Authors:  O Popelová; M Sterba; P Hasková; T Simůnek; M Hroch; I Guncová; P Nachtigal; M Adamcová; V Gersl; Y Mazurová
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.